MARKET

DFTX

DFTX

Definium Therapeutics
NASDAQ
15.38
+0.36
+2.40%
After Hours: 15.51 +0.13 +0.85% 19:46 01/15 EST
OPEN
15.11
PREV CLOSE
15.02
HIGH
15.49
LOW
14.75
VOLUME
1.02M
TURNOVER
--
52 WEEK HIGH
15.49
52 WEEK LOW
4.700
MARKET CAP
1.52B
P/E (TTM)
-7.7996
1D
5D
1M
3M
1Y
5Y
1D
Assessing Mind Medicine (MindMed) (DFTX) Valuation After Rebrand To Deinium Therapeutics And Pipeline Progress
Simply Wall St · 18m ago
*News On Mind Medicine (MindMed) Inc. (MNMD) Now Under DFTX
Dow Jones · 8h ago
Definium Therapeutics (Formerly Mind Medicine) Updates Nasdaq Listing Timeline; Common Shares To Begin Trading Under Ticker DFTX On January 15
Benzinga · 2d ago
MindMed Rebrands as Definium Therapeutics
Reuters · 2d ago
MindMed’s Rebrand To Definium Therapeutics And DT120 Pivot Could Be A Game Changer For Mind Medicine (MindMed) (MNMD)
Simply Wall St · 2d ago
Definium Therapeutics: De-Risked Late-Stage Neuropsychiatric Pipeline Positions 2026 as Catalyst-Rich Year Supporting Buy Rating and $32 Target
TipRanks · 3d ago
Definium Therapeutics Rebrands and Highlights 2026 Pipeline
TipRanks · 3d ago
Mind Medicine rebrands to Definium Therapeutics
TipRanks · 3d ago
More
About DFTX
Definium Therapeutics, Inc., formerly Mind Medicine (MindMed) Inc., is engaged in developing therapeutics intended to solve the underlying causes of psychiatric and neurological disorders and offer patients long-term remission rather than transient symptom reduction. The Company plans to advance DT1201 ODT toward FDA submissions in the two largest psychiatric markets, generalized anxiety disorder (GAD) and major depressive disorder (MDD). Its late-stage pipeline includes four Phase 3 trials, two each for GAD and MDD, anchored by its lead candidate, DT120 ODT, which has received an FDA Breakthrough Therapy Designation for GAD. In parallel, the Company is engaged in advancing its commercial strategy and operational readiness to support a care model and prepare for the launch of DT120 ODT, if approved and marketed. It also continues to advance its early-stage pipeline, having dosed the first patient in a Phase 2a study of DT4023 in adults with autism spectrum disorder (ASD).

Webull offers Definium Therapeutics Inc stock information, including NASDAQ: DFTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, DFTX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading DFTX stock methods without spending real money on the virtual paper trading platform.